Moderna

In this episode of MarketFoolery, host Chris Hill chats with analyst Emily Flippen about the latest quarterly results and news from Wall Street. They talk about why Moderna (NASDAQ:MRNA) is facing backlash from some quarters around its COVID-related announcements. Another healthcare provider posted robust earnings, beating market expectations. Also, Emily shares a stock to keep…

Moderna’s phase 1 data looks positive, but the company’s investigational coronavirus vaccine has a lot more to prove in late-stage trials. Moderna (NASDAQ:MRNA) has taken another step closer to making its dream of commercializing a coronavirus vaccine a reality. The company just released more detailed interim results from its phase 1 trial -- and they…

Moderna Inc.  (MRNA) - Get Report shares surged higher Wednesday after the drugmaker reported uniformly positive data from an early trial of its experimental coronavirus vaccine.Moderna said the phase 1 trial of MRNA-1273, its proposed coronavirus vaccine candidate, induced antibody reactions in all 45 patient participants, with no serious side-effects, following two injections spanning a four…

Published: July 14, 2020 at 6:23 p.m. ET New study shows ‘robust’ immune response to trial vaccine, Moderna says Moderna headquarters in Cambridge, Mass. Getty Images Moderna Inc. stock skyrocketed in the extended session Tuesday after the biotech company said its coronavirus vaccine candidate produced a “robust” immune-system response in a larger group of people…

Moderna's shares soared after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine.Moderna's stock rose more than 16% in after-hours trading on the news. All…